Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials
Publication Type:
Journal Article
Authors:
Jacobson, Ira M.;
Lawitz, Eric;
Gane, Edward J.;
Willems, Bernard E.;
Ruane, Peter J.;
Nahass, Ronald G.;
Borgia, Sergio M.;
Shafran, Stephen D.;
Workowski, Kimberly A.;
Pearlman, Brian;
Hyland, Robert H.;
Stamm, Luisa M.;
Svarovskaia, Evguenia;
Dvory-Sobol, Hadas;
Zhu, Yanni;
Subramanian, G. Mani;
Brainard, Diana M.;
McHutchison, John G.;
Bräu, Norbert;
Berg, Thomas;
Agarwal, Kosh;
Bhandari, Bal Raj;
Davis, Mitchell;
Feld, Jordan J.;
Dore, Gregory J.;
Stedman, Catherine A. M.;
Thompson, Alexander J.;
Asselah, Tarik;
Roberts, Stuart K.;
Foster, Graham R.Source:
Gastroenterology, Volume 153, Issue 1, p.113-122 (2017)
Keywords:
Adolescent,
Adult,
Aged,
Aged, 80 and over,
Antiviral Agents,
Carbamates,
clinical trial,
Comparison,
Direct-Acting Antiviral Agent,
Drug Therapy, Combination,
Female,
Hepatitis C, Chronic,
Heterocyclic Compounds, 4 or More Rings,
Humans,
Macrocyclic Compounds,
Male,
Middle Aged,
Shortened Duration Therapy,
sofosbuvir,
Sulfonamides,
sustained virologic response,
Young Adult
